Career history of Ted A. Laufik
Former positions of Ted A. Laufik
| Companies | Position | Start | End |
|---|---|---|---|
| Touche Ross & Co. | Corporate Officer/Principal | 1975-12-31 | 1981-12-30 |
Elcelyx Therapeutics, Inc.
 Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Director/Board Member | 2011-02-22 | - |
| Corporate Officer/Principal | 2011-02-22 | - | |
Morgenthaler Management Corp.
 Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler Management Corp (Morgenthaler Management) is a venture capital and private equity firm founded in 1968 by David Morgenthaler. The firm is headquartered in Portola Valley, California. | Director of Finance/CFO | 1984-12-31 | - |
| Public Communications Contact | 2011-01-19 | - |
Training of Ted A. Laufik
| Cleveland State University | Masters Business Admin |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 2 |
| Director of Finance/CFO | 1 |
| Public Communications Contact | 1 |
Sectoral
| Finance | 2 |
| Commercial Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Morgenthaler Management Corp.
Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler Management Corp (Morgenthaler Management) is a venture capital and private equity firm founded in 1968 by David Morgenthaler. The firm is headquartered in Portola Valley, California. | Finance |
| Touche Ross & Co. | Commercial Services |
Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elcelyx Therapeutics, Inc. develops novel therapeutics based on gut sensory modulation. Its product NewMet is being developed for use by type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. The firm also provides dietary supplements for weight management. The company was founded by Alain D. Baron in 2010 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Ted A. Laufik
- Experience
